BioCentury
ARTICLE | Clinical News

FDA accepts resubmitted NDA for Apricus' Vitaros

September 29, 2017 9:29 PM UTC

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc. (NASDAQ:APRI) to treat erectile dysfunction. The PDUFA date is Feb. 17, 2018.

Vitaros is a topical prostaglandin E1 (PGE1) cream formulated with the company's NexACT transdermal delivery technology...